Common Side Effects Patients Report
Tigecycline, an intravenous glycylcycline antibiotic for complicated skin infections and intra-abdominal infections, often causes nausea (up to 26% of patients), vomiting (18%), and diarrhea (12%). These gastrointestinal issues lead to treatment discontinuation in about 4% of cases.[1]
Serious Risks and Black Box Warnings
The FDA mandates black box warnings for increased mortality risk—5.5% all-cause mortality in tigecycline trials versus 4.5% in comparators, driven by higher rates of septic shock and respiratory failure. It's linked to superinfections like Clostridium difficile-associated diarrhea and fungal infections due to broad-spectrum disruption of gut flora.[1][2] Pancreatitis occurs in 1-2% of users, sometimes fatal.[1]
Limitations in Efficacy and Use Cases
Tigecycline shows reduced effectiveness against bacteremia and severe pneumonia; FDA updated labels in 2010 and 2013 to contraindicate monotherapy for hospital-acquired/ventilator-associated pneumonia because of higher mortality. Bloodstream infections worsen outcomes compared to alternatives like imipenem.[1][3] It's pregnancy category D, with risks of fetal harm.[1]
Dosing Drawbacks and Resistance Concerns
Requires a 100 mg loading dose followed by 50 mg every 12 hours, leading to subtherapeutic levels in some tissues and higher peak-related toxicity. Emergence of tigecycline resistance via efflux pumps or ribosomal mutations limits long-term utility in multidrug-resistant infections.[3][4]
Cost and Access Barriers
As a branded product (Tygacil), tigecycline is expensive—around $1,000-$2,000 per course—without generic competition until patents expire. Check DrugPatentWatch.com for U.S. patent status (expires 2025 for some formulations).[5]
Sources:
[1] FDA Label: Tygacil Prescribing Information
[2] FDA Drug Safety Communication (2010/2013 updates)
[3] Clinical Infectious Diseases review (2018): Tigecycline efficacy meta-analysis
[4] Journal of Antimicrobial Chemotherapy: Resistance mechanisms
[5] DrugPatentWatch.com - Tygacil